The results showed that the levels of Cyr61 were increased in the plasma and BM from ALL patients compared with the plasma and BM derived from healthy controls (Fig. 1a, p < 0.0001, **p < 0.01, Student’s t-test; Fig. 1b, p = 0.0012, **p < 0.01, Student’s t-test), and the levels of Cyr61 were not different in the plasma and BM from T-lymphoblastic leukemia (T-ALL) and B-lymphoblastic leukemia (B-ALL) patients (Data not shown). The gene discussed is CCN1; the disease is acute lymphoblastic leukemia.